What question did this study set out to answer?

December 8, 2025BloodOpen Access

Prophylactic rituximab administered on day -1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients

View Full Paper

Ask AI

Bookmark

Authors

SZSenlin Zhang QJQi Ji QWQingwei Wang

Discussion

Member takes

Implication

Retrospective analysis shows prophylactic rituximab lowers EBV reactivation and viral loads in pediatric allogeneic HSCT, suggesting improved outcomes.

Key Points

To evaluate the effectiveness of prophylactic rituximab administered on Day -1 during conditioning to reduce EBV reactivation in pediatric allo-HSCT.
Retrospective analysis of pediatric allo-HSCT patients from October 2010 to January 2025.
Patients were grouped by rituximab use during conditioning, administered at 375 mg/m² on Day -1.
Propensity scores were calculated and matched to create pairs for comparison, assessing balance.
Outcomes evaluated included EBV reactivation, engraftment, transplant-related complications, and immune recovery.
ABV reactivation in the rituximab group was 10.1% compared to 47.0% in non-rituximab group (p < 0.001).
Rituximab significantly reduced EBV viral loads among patients with reactivation (median loads: 11,400 vs. 51,200 copies/mL, p < 0.001).
Rituximab group demonstrated faster platelet engraftment (p = 0.013) without significant differences in other outcomes like OS and GRFS.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba7 https://doi.org/10.1182/blood-2025-5988

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows prophylactic rituximab lowers EBV reactivation and viral loads in pediatric allogeneic HSCT, suggesting improved outcomes.

Prophylactic rituximab administered on day -1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Prophylactic rituximab administered on day -1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider